APTEVO THERAPEUTICS INC.

Insiders Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Market Closed - Nasdaq Other stock markets 21:00:00 16/05/2024 BST			5-day change	1st Jan Change
0.7962 ^USD	-1.46%		-21.17%	-89.85%

05-08	Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-11	US Equity Markets Close Mixed After March Producer Price Inflation Data	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aptevo Therapeutics Inc. Appoints Jeffrey G. Lamothe to Executive Vice President, Chief Operating Officer	07/03/23	CI
Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight	06/07/22	CI
Aptevo Therapeutics' Board Chair to Retire, Successor Named	21/01/22	MT
Aptevo Therapeutics Inc. Announces Board Changes, Effective April 1, 2022	21/01/22	CI
Insider Sell: Aptevo Therapeutics	22/11/21	MT
Aptevo Therapeutics Inc. Announces Resignation of Jane Gross as Chief Scientific Officer, Effective September 14, 2021	27/08/21	CI
Aptevo Therapeutics Confirms Receipt of Nominations from Tang Capital	10/02/21	CI
Tang Capital Seeks to Nominate Candidates to Aptevo Therapeutics	09/02/21	CI
Insider Trends: Insider Acquisition Interrupts 90-Day Trend of Sales at Aptevo Therapeutics	06/11/20	MT
Scott Stromatt Resigns as Chief Medical Officer and SVP, Clinical Development & Medical Affairs of Aptevo Therapeutics Inc., Effective on October 31, 2019	28/10/19	CI
Aptevo Therapeutics Inc. Announces Executive Changes	15/09/16	CI
Aptevo Therapeutics Inc. Announces Board Appointments	02/08/16	CI
Emergent BioSolutions Announces Executive Management Team of Aptevo Therapeutics	21/01/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer